275 related articles for article (PubMed ID: 34872567)
1. Tumor antigens and immune subtypes guided mRNA vaccine development for kidney renal clear cell carcinoma.
Xu H; Zheng X; Zhang S; Yi X; Zhang T; Wei Q; Li H; Ai J
Mol Cancer; 2021 Dec; 20(1):159. PubMed ID: 34872567
[TBL] [Abstract][Full Text] [Related]
2. Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development.
Huang X; Tang T; Zhang G; Liang T
Mol Cancer; 2021 Mar; 20(1):50. PubMed ID: 33685460
[TBL] [Abstract][Full Text] [Related]
3. Recognition of Tumor-Associated Antigens and Immune Subtypes in Glioma for mRNA Vaccine Development.
Ma S; Ba Y; Ji H; Wang F; Du J; Hu S
Front Immunol; 2021; 12():738435. PubMed ID: 34603319
[TBL] [Abstract][Full Text] [Related]
4. Identification of Tumor Antigens and Immune Subtypes of Glioblastoma for mRNA Vaccine Development.
Lin H; Wang K; Xiong Y; Zhou L; Yang Y; Chen S; Xu P; Zhou Y; Mao R; Lv G; Wang P; Zhou D
Front Immunol; 2022; 13():773264. PubMed ID: 35185876
[TBL] [Abstract][Full Text] [Related]
5. Tumor-antigens and immune landscapes identification for prostate adenocarcinoma mRNA vaccine.
Zheng X; Xu H; Yi X; Zhang T; Wei Q; Li H; Ai J
Mol Cancer; 2021 Dec; 20(1):160. PubMed ID: 34872584
[TBL] [Abstract][Full Text] [Related]
6. LRP2 and DOCK8 Are Potential Antigens for mRNA Vaccine Development in Immunologically 'Cold' KIRC Tumours.
Zhang S; Xia K; Chang Y; Wei Y; Xiong Y; Tang F; Peng J; Ouyang Y
Vaccines (Basel); 2023 Feb; 11(2):. PubMed ID: 36851274
[TBL] [Abstract][Full Text] [Related]
7. Dissecting Tumor Antigens and Immune Subtypes of Glioma to Develop mRNA Vaccine.
Zhong H; Liu S; Cao F; Zhao Y; Zhou J; Tang F; Peng Z; Li Y; Xu S; Wang C; Yang G; Li ZQ
Front Immunol; 2021; 12():709986. PubMed ID: 34512630
[TBL] [Abstract][Full Text] [Related]
8. Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development.
Huang X; Zhang G; Tang T; Liang T
Mol Cancer; 2021 Mar; 20(1):44. PubMed ID: 33648511
[TBL] [Abstract][Full Text] [Related]
9. Dissection of tumor antigens and immune landscape in clear cell renal cell carcinoma: Preconditions for development and precision medicine of mRNA vaccine.
Hu J; Mo Z
Math Biosci Eng; 2023 Jan; 20(2):2157-2182. PubMed ID: 36899527
[TBL] [Abstract][Full Text] [Related]
10. Identification of three tumor antigens and immune subtypes for mRNA vaccine development in diffuse glioma.
Zhou Q; Yan X; Zhu H; Xin Z; Zhao J; Shen W; Yin W; Guo Y; Xu H; Zhao M; Liu W; Jiang X; Ren C
Theranostics; 2021; 11(20):9775-9790. PubMed ID: 34815785
[No Abstract] [Full Text] [Related]
11. Gene set enrichment analysis identifies immune subtypes of kidney renal clear cell carcinoma with significantly different molecular and clinical properties.
Chen Z; Cao W; Luo J; Abdelrahman Z; Lu Q; Wang H; Wang X
Front Immunol; 2023; 14():1191365. PubMed ID: 37426638
[TBL] [Abstract][Full Text] [Related]
12. Identification of tumor antigens and immune landscapes for bladder urothelial carcinoma mRNA vaccine.
Sun Z; Jing C; Zhan H; Guo X; Suo N; Kong F; Tao W; Xiao C; Hu D; Wang H; Jiang S
Front Immunol; 2023; 14():1097472. PubMed ID: 36761744
[TBL] [Abstract][Full Text] [Related]
13. Unique protein expression signatures of survival time in kidney renal clear cell carcinoma through a pan-cancer screening.
Han G; Zhao W; Song X; Kwok-Shing Ng P; Karam JA; Jonasch E; Mills GB; Zhao Z; Ding Z; Jia P
BMC Genomics; 2017 Oct; 18(Suppl 6):678. PubMed ID: 28984208
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive characterization of immune- and inflammation-associated biomarkers based on multi-omics integration in kidney renal clear cell carcinoma.
Zhao E; Li L; Zhang W; Wang W; Chan Y; You B; Li X
J Transl Med; 2019 May; 17(1):177. PubMed ID: 31133033
[TBL] [Abstract][Full Text] [Related]
15. Identification of tumor antigens and immune subtypes of acute myeloid leukemia for mRNA vaccine development.
Wang F
Clin Transl Oncol; 2023 Jul; 25(7):2204-2223. PubMed ID: 36781600
[TBL] [Abstract][Full Text] [Related]
16. Screening of Tumor Antigens and Construction of Immune Subtypes for mRNA Vaccine Development in Head and Neck Squamous Cell Carcinoma.
Li HX; Liu TR; Tu ZX; Xie CB; Wen WP; Sun W
Biomolecules; 2022 Dec; 13(1):. PubMed ID: 36671475
[TBL] [Abstract][Full Text] [Related]
17.
Klümper N; Ralser DJ; Bawden EG; Landsberg J; Zarbl R; Kristiansen G; Toma M; Ritter M; Hölzel M; Ellinger J; Dietrich D
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32234847
[TBL] [Abstract][Full Text] [Related]
18. Multi-omics analysis of tumor angiogenesis characteristics and potential epigenetic regulation mechanisms in renal clear cell carcinoma.
Zheng W; Zhang S; Guo H; Chen X; Huang Z; Jiang S; Li M
Cell Commun Signal; 2021 Mar; 19(1):39. PubMed ID: 33761933
[TBL] [Abstract][Full Text] [Related]
19. Cuproptosis status affects treatment options about immunotherapy and targeted therapy for patients with kidney renal clear cell carcinoma.
Zhang G; Chen X; Fang J; Tai P; Chen A; Cao K
Front Immunol; 2022; 13():954440. PubMed ID: 36059510
[TBL] [Abstract][Full Text] [Related]
20. mRNA-based precision targeting of neoantigens and tumor-associated antigens in malignant brain tumors.
Trivedi V; Yang C; Klippel K; Yegorov O; von Roemeling C; Hoang-Minh L; Fenton G; Ogando-Rivas E; Castillo P; Moore G; Long-James K; Dyson K; Doonan B; Flores C; Mitchell DA
Genome Med; 2024 Jan; 16(1):17. PubMed ID: 38268001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
